Search

Your search keyword '"Dulai PS"' showing total 239 results

Search Constraints

Start Over You searched for: Author "Dulai PS" Remove constraint Author: "Dulai PS"
239 results on '"Dulai PS"'

Search Results

1. High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis

2. Magnetic resonance elastography identifies fibrosis in adults with alpha‐1 antitrypsin deficiency liver disease: a prospective study

Catalog

Books, media, physical & digital resources

5. Digital Therapeutics Care Utilizing Genetic and Gut Microbiome Signals for the Management of Functional Gastrointestinal Disorders: Results from a Preliminary Retrospective Study

7. A Review of the Modified Multiplier of SES-CD (MM-SES-CD) and How to Use in Clinical Trials and Practice.

8. Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis.

9. Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease.

10. Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial.

11. Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.

14. Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.

15. Provider Education and Clinical Decision Support Tool Improve Proficiency in Advanced Therapies for Inflammatory Bowel Disease.

16. Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy.

17. Use of MM-SES-CD Endoscopic Improvement Thresholds Enhances Effect Size Differentiation between Adalimumab vs. Placebo: A Post-hoc Analysis of the EXTEND Trial.

18. Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis.

19. Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease.

20. Acute severe ulcerative colitis trials: the past, the present and the future.

21. Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.

22. Resolution of Rectal Bleeding by Day 7 in Acute Severe Ulcerative Colitis Is Prognostic for Postdischarge Corticosteroid-Free Clinical Remission and Endoscopic Improvement.

23. Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression.

24. Pangenome comparison of Bacteroides fragilis genomospecies unveils genetic diversity and ecological insights.

25. Longitudinal gut microbial signals are associated with weight loss: insights from a digital therapeutics program.

26. Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.

27. Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer.

28. Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis.

29. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.

30. Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases.

31. Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019).

33. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.

34. Author Correction: Enhancing untargeted metabolomics using metadata-based source annotation.

35. Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.

36. Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease.

37. Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa.

38. Correlations Between Gastrointestinal Symptoms and Endoscopic-Histologic Disease Activity in Adults with Ulcerative Colitis.

39. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis.

40. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.

41. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.

42. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.

43. Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study.

44. Role of hyperbaric oxygen therapy in patients with inflammatory bowel disease.

45. The importance of predicting patient responses to monoclonal antibodies for Crohn's disease.

46. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.

47. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.

48. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.

49. The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease.

50. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease.